AstraZeneca-Bristol Myers Talks Spark Share Moves, Analyst Skepticism

AstraZeneca shares declined sharply on Monday after reports emerged that the British pharmaceutical company had held preliminary discussions about acquiring Bristol Myers Squibb in a transaction that could reach roughly $400 billion. The talks, first reported by the Financial Times, would rank among the largest pharmaceutical mergers in history and create one of the world's largest drugmakers by market value. Neither company has confirmed the discussions, and AstraZeneca declined to comment while Bristol Myers did not respond outside normal business hours.

AstraZeneca's London-listed shares fell as much as 7 percent before closing the session 4.7 percent lower, pressuring the broader FTSE 100 index. Bristol Myers shares rose 6 to 8 percent in premarket trading in New York. The proposed combination would give AstraZeneca a significantly expanded footprint in the United States, where the company already plans to invest $50 billion in research and manufacturing through 2030. AstraZeneca completed a direct listing on the New York Stock Exchange in June.

Analysts expressed surprise at the reported talks, noting that AstraZeneca has delivered consistent growth under chief executive Pascal Soriot since 2012. The company reported sales of $58.7 billion last year and has set a target of $80 billion by 2030, driven by a pipeline that includes several high-performing oncology and cardiovascular medicines. Its market capitalization stood near $264 billion before the news broke. Bristol Myers, by contrast, carries a market value of about $133 billion and faces the expiration of key patents on major products including the blood thinner Eliquis and the cancer therapy Opdivo, which are expected to encounter generic competition starting next year.

The potential overlap in oncology portfolios drew particular attention from analysts, who said any deal would face close regulatory examination on both sides of the Atlantic. Jefferies analysts noted that while a merged entity would hold the broadest oncology portfolio in the industry, many pipeline assets could be obtained through smaller acquisitions or partnerships rather than a full-scale merger. They questioned the strategic logic given AstraZeneca's independent momentum.

A transaction would also revive long-standing debates in Britain about whether large domestic companies are drifting toward greater dependence on the American market. AstraZeneca is the second-largest listed company in the United Kingdom by market value, and any shift in its operational center of gravity could affect employment, tax revenue, and the country's standing in life-sciences research.

Industry observers pointed out that consolidation in pharmaceuticals has accelerated in recent years as companies seek scale to offset rising development costs and pricing pressure from governments and insurers. A combined AstraZeneca-Bristol Myers entity would hold substantial negotiating leverage with payers, yet it would also concentrate ownership of several leading cancer treatments at a time when regulators have shown greater willingness to scrutinize deals that reduce competition in narrowly defined therapeutic areas.

Details of the reported discussions remain limited, and sources indicated that no agreement is assured. The episode nevertheless underscores the differing trajectories of the two companies and the broader pressures reshaping the sector as patents expire and new regulatory frameworks emerge in both Europe and the United States.